Sanofi Claims IP Life Extension Needed For Double Patenting
The Patent Trial and Appeal Board rightly found a Sanofi patent application shouldn't be rejected for obviousness-type double patenting, as it doesn't improperly extend patent life, the French drugmaker and its...To view the full article, register now.
Already a subscriber? Click here to view full article